Zambon announces approval and ARTG listing of safinamide in Australia for treatment of patients with Parkinson’s disease

Zambon announces approval and ARTG listing of safinamide in Australia for treatment of patients with Parkinson’s disease

05 December 2018 - Announced the recent approval of Xadago®/safinamide in Australia by the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health for the treatment of adult patients with fluctuating idiopathic Parkinson’s disease (PD)

Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system therapeutic area, and its partner Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announce the recent approval of Xadago®/safinamide in Australia by the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health for the treatment of adult patients with fluctuating idiopathic Parkinson’s disease (PD) as add-on therapy to a regimen that includes levodopa (L-Dopa).

For more information: https://www.newron.com/en

Where to find us

20149 Milan
Via Giovanni da Procida, 11
Show map 
Tel. +39 02.34565.1
Fax. +39 02.34565.310
Segreteria Assobiotec
Tel. 02 34565.256/341
assobiotec@federchimica.it